

## Project Partner Search Form

- I offer my expertise to participate as a Partner in a Horizon Europe Project
- I am planning to coordinate a project and I am looking for Project Partners

### TOPICS OF INTEREST

Vaccines 2.0 - developing the next generation of vaccines  
TOPIC ID: HORIZON-HLTH-2022-DISEASE-06-03-two-stage

Development of new effective therapies for rare diseases  
TOPIC ID: HORIZON-HLTH-2022-DISEASE-06-04-two-stage **done**

Pandemic preparedness  
TOPIC ID: HORIZON-HLTH-2022-DISEASE-07-0 done

Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)  
TOPIC ID: HORIZON-HLTH-2022-DISEASE-07-01 done

European partnership fostering a European Research Area (ERA) for health research  
TOPIC ID: HORIZON-HLTH-2022-DISEASE-03-01

Develop new methods and technologies for cancer screening and early detection  
TOPIC ID: HORIZON-MISS-2021-CANCER-02-01

### PARTNER INFORMATION

Benten Biotech ([www.bentenbiotech.com](http://www.bentenbiotech.com)) is an SME that develops innovative products and processes in biotechnology, focused on animal and human health. Within our areas of expertise are the discovery, R&D and production for preclinical phases of monodomain recombinant monoclonal antibodies (VHH antibodies, recombinant monodomain antibodies). Within the capabilities of our platform is native or recombinant antigens development, and its standardization for immunoassays or immunotherapies based on monodomain antibodies. At Benten we are continually looking for partners that allow us to enhance joint value propositions, co-develop new products or processes to quickly advance in the development of health solutions. We are particularly interested in participating in innovation clusters with companies from the EU or associated countries, to contribute in phases of discovery, R&D as well as with preclinical candidates in immunodiagnostics and immunotherapies using VHH antibodies. We need partners to perform clinical phases or IVD validation for the products based in VHH antibodies candidates that Benten develops. [info@bentenbiotech.com](mailto:info@bentenbiotech.com)

#### **Description of the Legal Entity**

- |   |   |  |
|---|---|--|
| <input type="checkbox"/> Higher Education         | <input type="checkbox"/> Research Institution | <input type="checkbox"/> Public Administration               |
| <input checked="" type="checkbox"/> Industry /SME | <input type="checkbox"/> NGO                  | <input type="checkbox"/> Other: <b><i>Please specify</i></b> |



### **Description of the (Research) Team**

The company Benten Biotech SRL is a biotechnology company in its fifth year of existence. The partners in charge of the company are Dr. Esteban Guerra and PhD. Jorge Wenzel. Dr. Guerra has the general director role. The PhD. Jorge Wenzel acts as a general project manager. Benten, has research and development laboratories with state-of-the-art equipment, located in the LATU-Uruguay ([www.latu.org.uy](http://www.latu.org.uy)), the facilities include areas for the development of recombinant antibodies, recombinant proteins, bacteriology and virology with a focus on antigens standardization. The main value proposition of Benten is their scientific team capabilities: Msc Lucía Rodríguez: she is the professional responsible for the production, purification and standardization of antigens and neutralizing antibodies for experimental vaccines or antibodies production. The PhD Triana Delfín is responsible for the development and production of recombinant monodomain VHH antibodies, and from them, in vitro quantification systems (ELISA and other Immunochromatographic techniques) are developed against different antigens of interest. The PhD Sofía Tabarez is jointly responsible for the area of VHH antibodies but focused on immunotherapies. The PhD María Lamas is responsible for the area of evaluation of the immune response in animal models of the biological formulations developed in Benten in both pre-clinical and veterinary clinical research and development stages. Benten has an extensive network of professionals in various public and private institutions that complement and support our activities.

This team has been directing multiple innovation and development projects for the healthcare industry for several years. These projects are being unraveled not only in Uruguay but also for companies from countries on 3 continents. Sofía Tabarez, Triana Delfín, María Lamas and Jorge Wenzel are categorized in the National Reserchers System of Uruguay (SNI) (<https://sni.org.uy/>)

### **Expertise of the Team Leader**

Dr. Guerra is a veterinarian, has 20 years of experience in the development of products and processes and also in process set up in the veterinary biological industry. His vision in the biotechnology area led him to found Benten Biotech SRL in 2016 with the mission of developing high value-added products and services in the health area from Uruguay, his native country. Today he is the CEO of Benten Biotech. Dr. Guerra has led the development and implementation of products and processes in the industry in countries such as Brazil, Turkey, and Argentina. Since the founding of Benten, he has led the team in projects for private laboratories in the countries already mentioned, adding laboratories from Colombia, Brazil, Romania, Jordan and Guatemala. In the field of innovation projects in the biotechnological area of health making use of public funds for calls and surrender by audit, Dr. Guerra is currently the Director of the following projects of the National Research and Innovation Agency of Uruguay (ANII), under development: ANII ART\_X\_2021\_1\_170466 "Development of replacement recombinant standards for clostridial toxin neutralizing sera and kits in-vitro quantification of the same, for use in the veterinary vaccine production industry"; ANII HPI\_X\_2021\_1\_169615 "Generation of recombinant monodomain VHH antibodies with specificity for the non-structural protein of Zika, which allow the development of immunoassays for the diagnosis of the virus"; ANII HPI\_X\_2021\_1\_166791 "Generation of antibodies (HHV) with specificity for virulence antigens of Clostridium chauvoei"; ANII IDI\_X\_2020\_1\_160864 "Development of products for the reproductive control of canines (immuno-IVD and immunocontraception using VHH antibodies); ANII IDI\_X\_2019\_1\_158488 "Development of products to improve passive immunity in Equines" And he has been

[www.bentenbiotech.com](http://www.bentenbiotech.com)  
[info@bentenbiotech.com](mailto:info@bentenbiotech.com)  
Parque LATU-11500 Monevideo  
Uruguay

scientific director the following projects already completed: National Directorate of Industries, Ministry of Industries Uruguay. Biotechnological Found 2020 - "Therapeutic Antibody Development Platform"; ANII HPI\_X\_2019\_1\_160863-Production and evaluation at the field level of experimental vaccines for Neosporosis ANII IDI\_X\_2019\_1\_154920-PLATFORM FOR RESEARCH, DEVELOPMENT, INNOVATION AND PRODUCTION OF AUTOGENOUS VACCINES (I + D + i + P Platform); ANII HPI\_X\_2017\_1\_137775-Quality control of veterinary vaccines; ANII HPI\_X\_2017\_1\_143906 "Development of a process for the in vitro production of the attenuated hemoparasite Babesia bovis, for its use as a component of the vaccine against Bovine Parasitic Tristeza"

**Potential role in the project**

- Research
- Training
- Dissemination
- Other: *Please specify*

Already experience as a	Coordinator	<input type="checkbox"/> YES	<input checked="" type="checkbox"/> NO
	Partner	<input type="checkbox"/> YES	<input checked="" type="checkbox"/> NO
	Expert Evaluator	<input type="checkbox"/> YES	<input checked="" type="checkbox"/> NO

**CONTACT DETAILS**

Contact Person: Jorge Wenzel
Organization: Benten Biotech
City: Montevideo
Country: Uruguay
Phone: +598 98969939
Email: jorgewenzel@bentenbiotech.com
Organization Website: www.bentenbiotech.com
Contact Person Webpage:

Date: 24/12/2021



*Please send this form back to your NCP*